PATENT CLAIM ANALYSIS

Application Number: 16032270
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "400000"]

Abstract:
Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.

Claim (Index 1):
A method of treating a disease, disorder or condition that is therapeutically responsive to risperidone or metabolite thereof, the method comprising administering to a subject in need thereof an amount of injectable depot composition sufficient to provide a therapeutic dose of risperidone, to form an implant in the subject, wherein the injectable depot composition consists of risperidone, and a polymeric solution of DMSO and PLGA copolymer, and wherein:\n the content of risperidone is 13% wt \u00b110%, based upon the weight of the composition, and the risperidone possesses a particle distribution selected from:\n a. not more than 10% of the total volume of the particles is smaller than 10 microns, not more than the 10% of the total volume of particles is greater than 225 microns, and the d0.5 is in the range of 10-200 microns; \n b. not more than 10% of the total volume of the particles is less than the range 1-10 \u03bcm, not more than the 10% of the total volume of particles is greater than the range 225-400 \u03bcm, and the d0.5 of the size distribution is in the range of about 40-200 \u03bcm; or \n c. expressed as volume, d0.9 is about 150 to about 400 \u03bcm, d0.5 is about 40 to about 200 \u03bcm and d0.1 is about 10 to about 60 \u03bcm; \n the mass ratio of DMSO to risperidone is 4.66\u00b110%:1; the mass ratio of polymeric solution to risperidone is about 6.66\u00b110%:1; the PLGA copolymer is an end-capped biodegradable poly(lactide-co-glycolide) copolymer having a monomer ratio of lactic acid to glycolic acid of 50:50 and an inherent viscosity in the range of 0.20\u00b110% dl/g to 0.50\u00b110% dl/g as measured in chloroform at 25\u00b0 C. at a concentration of 0.1% wt/v with an Ubbelohde size Oc glass capillary viscometer; the polymeric solution has a viscosity in the range of 0.5-3.0 Pa\u00b7s; and the amount of risperidone dissolved in the injectable composition is \u226420% wt.

Metadata:
- Claim Count in Document: 68.0
- Percentile: 95.0
- Lexical Diversity: 1.4375
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13690707', '15944894', '13690647', '14555287', '14610362']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7860795644257039
- 35 USC 102 Novelty (BERT): 0.6525195067106109
- Combined Prediction Score: 0.7727235586541946
- Mean Citation Score: 493.552822
- Max Citation Score: 740.9466
- Similarity Product: 586.4214091447592

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test